Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Metagenomi Therapeutics, Inc. - Common Stock (NQ:MGX)

1.280 -0.050 (-3.76%)
Streaming Delayed Price Updated: 1:23 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 157,122
Open 1.290
Bid (Size) 1.280 (4,000)
Ask (Size) 1.290 (400)
Prev. Close 1.330
Today's Range 1.280 - 1.310
52wk Range 1.240 - 3.950
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-23.4%
-23.4%
1 Month
-9.2%
-9.2%
3 Month
-20.5%
-20.5%
6 Month
-28.5%
-28.5%
1 Year
-24.7%
-24.7%

More News

Read More
News headline image
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present at Jefferies Global Healthcare Conference in London
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Inc (NASDAQ:MGX) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected ↗
Via Chartmill
News headline image
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Which stocks are gapping on Wednesday? ↗
Via Chartmill
News headline image
Sam Altman Says He 'Didn't Think' Elon Musk Would Abuse Government Power, Tesla CEO Hits Back With 'Scam Altman' Jibe ↗
Via Benzinga
News headline image
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗
Via Benzinga
News headline image
Demystifying Metagenomi: Insights From 4 Analyst Reviews ↗
Via Benzinga
News headline image
Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Via Benzinga
News headline image
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present at Upcoming Scientific Meetings
From Metagenomi, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Metagenomi Therapeutics, Inc. - Common Stock publicly traded?
Yes, Metagenomi Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Metagenomi Therapeutics, Inc. - Common Stock trade on?
Metagenomi Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Metagenomi Therapeutics, Inc. - Common Stock?
The ticker symbol for Metagenomi Therapeutics, Inc. - Common Stock is MGX on the Nasdaq Stock Market
What is the current price of Metagenomi Therapeutics, Inc. - Common Stock?
The current price of Metagenomi Therapeutics, Inc. - Common Stock is 1.280
When was Metagenomi Therapeutics, Inc. - Common Stock last traded?
The last trade of Metagenomi Therapeutics, Inc. - Common Stock was at 06/05/26 01:23 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.